ArticleCancers2018
AR Signaling in Human Malignancies: Prostate Cancer and Beyond.
Article in Cancers, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 23 citations in OpenAlex.
- Elevated Tumor-Associated Androgen Receptor Activity Correlates with Poor Immune Infiltration and Immunotherapy Response across Cancer Types.Cancer research communications · 2026Article
- Secondary Cancer after Androgen Deprivation Therapy in Prostate Cancer: A Nationwide Study.The world journal of men's health · 2025Article
- Dysregulated LINC01133 expression in laryngeal carcinoma: Prognostic implications and predicted ceRNA interactome.Molecular biology research communications · 2025Article
- Sex difference in human diseases: mechanistic insights and clinical implications.Signal transduction and targeted therapy · 2024Review
- Androgen receptor activity inversely correlates with immune cell infiltration and immunotherapy response across multiple cancer lineages.bioRxiv : the preprint server for biology · 2024Article
- Sex-specific outcomes in cancer therapy: the central role of hormones.Frontiers in medical technology · 2024Review
- AR activates YAP/TAZ differentially in prostate cancer.Life science alliance · 2023Article
- Enzalutamide Induces Apoptotic Insults to Human Drug-Resistant and -Sensitive Glioblastoma Cells via an Intrinsic Bax-Mitochondrion-Cytochrome C Caspase Cascade Activation Pathway.Molecules (Basel, Switzerland) · 2022Article
- Informal caregiver burden for solid tumour cancer patients: a review and future directions.Psychology & health · 2021Review
- Hormone therapy for ovarian cancer: Emphasis on mechanisms and applications (Review).Oncology reports · 2021Review
- Mining the plasma-proteome associated genes in patients with gastro-esophageal cancers for biomarker discovery.Scientific reports · 2021Article
- Long non-coding RNA TMPO-AS1 promotes tumor progression via sponging miR-140-5p in breast cancer.Experimental and therapeutic medicine · 2021Article
- RNA Sequencing of the NCI-60: Integration into CellMiner and CellMiner CDB.Cancer research · 2019Article
- Androgen receptor gene methylation related to colorectal cancer risk.Endocrine connections · 2019Article
- Dihydrotestosterone increases the risk of bladder cancer in men.Human cell · 2019Article
- Androgen Receptor-CaMKK2 Axis in Prostate Cancer and Bone Microenvironment.Frontiers in endocrinology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The notion that androgens and androgen receptor (AR) signaling are the hallmarks of prostate cancer oncogenesis and disease progression is generally well accepted. What is more poorly understood is the role of AR signaling in other human malignancies. This special issue of
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.